AssetMark Inc’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

AssetMark Inc’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-379	Closed	-$40.7K	–	1708
2023 Q1	$40.7K	Buy	+379	New	+$43.6K	﹤0.01%	1079

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

AssetMark Inc's RXDX Position: Q2 2023 in Review

AssetMark Inc sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 379 shares — an estimated $40.7K sold.

AssetMark Inc first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $40.7K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

AssetMark Inc reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
AssetMark Inc sold 379 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $40.7K.
AssetMark Inc first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
AssetMark Inc's Prometheus Biosciences, Inc. Common Stock position peaked at $40.7K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on AssetMark Inc's 13F filing for Q2 2023, filed 11 Aug 2023.